Adamis Pharmaceuticals (ADMP:NASDAQ) Investor Relations Material

Overview

San Diego-based Adamis Pharmaceuticals Corporation, a biopharmaceutical company that specializes in the development and commercialization of products for various therapeutic areas, has added new items to its portfolio. The company's products are aimed at treating allergy, opioid overdose, respiratory, and inflammatory diseases. Among them are SYMJEPI epinephrine injectable pre-filled single-dose syringe products that can be used in emergency situations to treat acute allergic reactions, including anaphylaxis. Adamis also offers the ZIMHI naloxone injection to battle opioid overdose. The company was established in 2006 with its headquarters in San Diego, California.

Frequently Asked Questions

What is Adamis Pharmaceuticals's ticker?

Adamis Pharmaceuticals's ticker is ADMP

What exchange is Adamis Pharmaceuticals traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Adamis Pharmaceuticals's headquarters?

They are based in San Diego, California

How many employees does Adamis Pharmaceuticals have?

There are 51-200 employees working at Adamis Pharmaceuticals

What is Adamis Pharmaceuticals's website?

It is adamispharmaceuticals.com

What type of sector is Adamis Pharmaceuticals?

Adamis Pharmaceuticals is in the Healthcare sector

What type of industry is Adamis Pharmaceuticals?

Adamis Pharmaceuticals is in the Drug Delivery industry

Who are Adamis Pharmaceuticals's peers and competitors?

The following five companies are Adamis Pharmaceuticals's industry peers:

- Nektar Therapeutics

- Delcath Systems

- Adamis Pharmaceuticals

- Pets at Home Group

- Acura Pharmaceuticals, Inc.